To bolster the increased demand for mRNA therapies, Germany’s Evonik Industries, in partnership with the U.S. government, is investing more than $200 million to build a lipid manufacturing facility in the United States.
Pfizer Inc. and partner BioNTech completed the filing with the U.S. drugs regulator seeking authorization for their COVID-19 vaccine in children under 5 years of age.
Pfizer Inc. will make all of the company’s patented medicines including the COVID-19 treatment Paxlovid and big-selling breast cancer drug Ibrance available at a not-for-profit price to 45 of the world’s poorest countries, the drugmaker said on Wednesday.
Omicron breakthrough infections may spare young hearts; no need to delay mammogram after vaccinationAntibodies, BioNTech, BNT162b2 (Pfizer and BioNTech), Breakthrough COVID-19, Cardiovascular, COVID-19 booster shots, COVID-19 shots, COVID-19 Studies, COVID-19 Vaccinations, COVID-19 Vaccines, Covid-19 Variants, Heart, Immune Cells, Immune Response, Lancet Infectious Diseases, Mammography, Messenger RNA (mRNA) Vaccines, Omicron (B.1.1.529) (South Africa), Pfizer, R&D, T-Cells, Women
The Omicron variant of the coronavirus does not have a negative effect on cardiovascular health in young adults who have been vaccinated, a small study suggests. Additionally, women should not delay routine mammograms after receiving a COVID-19 mRNA vaccine, experts now say.
Drugmakers Pfizer Inc and BioNTech SE said on May 23 that three doses of their COVID-19 vaccine generated a strong immune response in children under age 5 and was safe and well-tolerated in their clinical trial.
The U.S. Food and Drug Administration set June 14-15 as the new meeting date to review Moderna Inc.’s emergency authorization request for the company’s COVID-19 vaccine for children aged 6 months to 5 years and Pfizer Inc.’s vaccine for those aged 6 months through 4 years.